Amgen has posted higher sales in Q2 2018 boosted by double-dgitig growth from some of its recently launched products. Revenue rose by 4% to $6.1 billion, above forecasts $5.7 billion. CEO Robert Bradway noted that "our two most recently launched products, Aimovig and Parsabiv, are off to a strong start".
Astellas reported higher first-quarter sales of $3 billion and a 28.5% increase profit to $491 million. This was despite revenue falling 12.3% in Japan on the back of NHI price revisions implemented in April and generic competition for Micardis in the country.
AstraZeneca's cancer drugs were the main drivers behind its second-quarter revenues of $5.2 billion, an increase of 2%. "The performance in the first half demonstrated that we remain firmly on track to return our company to product sales growth in 2018," said CEO Pascal Soriot. Oncology product sales were up 44% to $1.4 billion, with Tagrisso seeing an impressive rise in revenues of 82% to $422 million.
Bristol-Myers Squibb saw revenue grow by 11% to $5.7 billion in Q2. Notably both Eliquis and Opdivo beat analysts’ predictions to bring in revenues of $1.7 billion (up 40%) and $1.6 billion (up 36%) respectively. "We had a very good second quarter where we delivered strong performance for Eliquis and Opdivo," said CEO Giovanni Caforio. “Looking forward, we are focused on robust commercial execution and the evolution of our diversified pipeline to deliver transformational medicines to the patients we serve."
Celgene lifted its full-year guidance after sales rose 17% to $3.8 billion for Q2. Its big performers were Revlimid, which saw revenues boosted by 21% to $2.5 billion, and Pomalyst/Imnovid, which brought in revenues of $507 million, up 30 percent. Both of these results were attributed to increased market share and extended treatment duration. The company now expects revenue of about $15 billion for the year, compared to an earlier estimate of $14.8 billion.